LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it is tripling the number of patients in its Phase 1b/2 clinical trial who will be treated with its tumor-targeting doxorubicin conjugate INNO-206 at the dose planned for its Phase 2b trial for the treatment of advanced soft tissue sarcomas. Six patients have already been treated at that dose, out of a total of 13 enrolled in the trial, and the Company now plans to add an additional 12 patients. The open-label safety and dose escalation Phase 1b clinical trial has now been designated a Phase 1b/2 trial, and is being conducted primarily in patients with advanced soft tissue sarcomas who have failed standard therapies.
